Get the Stockscreener App
67.71
1.67%
-1.15
Pre-market:
68.60
0.89
+1.31%
Oruka Therapeutics Inc stock is traded at $67.71, with a volume of 816.20K.
It is down -1.67% in the last 24 hours and up +9.33% over the past month.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
See More
Previous Close:
$68.86
Open:
$69.05
24h Volume:
816.20K
Relative Volume:
0.53
Market Cap:
$4.08B
Revenue:
-
Net Income/Loss:
$-116.25M
P/E Ratio:
-28.32
EPS:
-2.3912
Net Cash Flow:
$-91.19M
1W Performance:
+1.17%
1M Performance:
+9.33%
6M Performance:
+133.97%
1Y Performance:
+444.73%
1-Day Range:
$66.68
$69.65
1-Week Range:
$63.95
$71.72
52-Week Range:
$10.77
$91.00
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
67.71 | 4.15B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Piper Sandler | Overweight |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics COO Laura Sandler sells $41,814 in ORKA shares - Investing.com
Oruka Therapeutics general counsel Paul Quinlan sells $51,082 in stock - Investing.com
Oruka Therapeutics CMO Joana Goncalves sells $550,606 in stock - Investing.com
Oruka Therapeutics SVP of finance Arjun Agarwal sells $687k in stock By Investing.com - Investing.com India
Oruka Therapeutics general counsel Paul Quinlan sells $51,082 in stock By Investing.com - Investing.com India
Oruka Therapeutics (ORKA) SVP exercises options, sells shares to cover tax obligations - Stock Titan
Oruka Therapeutics (ORKA) CMO sells shares and exercises stock options - Stock Titan
Oruka Therapeutics (ORKA) CEO has 1,729 shares sold for RSU tax withholding - Stock Titan
Oruka Therapeutics (ORKA) COO sells 600 shares to cover taxes - Stock Titan
Oruka Therapeutics (ORKA) counsel sells 733 shares in tax sell-to-cover - Stock Titan
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade - MSN
Insider Sell: Carl Dambkowski Sells 35,000 Shares of Oruka Thera - GuruFocus
Certain Warrants of Oruka Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JUN-2026. - marketscreener.com
Certain Series B Preferred Stock of Oruka Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JUN-2026. - marketscreener.com
Oruka Therapeutics (ORKA) director sells 35,000 shares under Rule 10b5-1 plan - Stock Titan
Oruka Therapeutics, Inc. (ORKA) upgraded to buy: What does it mean for the stock? - MSN
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
ORKA (NASDAQ: ORKA) notice to sell 35,000 shares; insider sold 105,000 - Stock Titan
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
ORKA News | ORUKA THERAPEUTICS INC (NASDAQ:ORKA) - ChartMill
Basic earnings per share (basic EPS) of Oruka Therapeutics, Inc. – XETR:HQ1 - TradingView
Is Oruka’s Broadened IL-23 License Reshaping Optionality And Altering The Investment Case For Oruka Therapeutics (ORKA)? - simplywall.st
Gross margin % of Oruka Therapeutics, Inc. – XETR:HQ1 - TradingView
Asset turnover of Oruka Therapeutics, Inc. – XETR:HQ1 - TradingView
Oruka Therapeutics, Inc. Statistics – XETR:HQ1 - TradingView
Oruka Therapeutics, Inc. Income Statement – XETR:HQ1 - TradingView
ETFs Investing in Oruka Therapeutics, Inc. Stocks - TradingView
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
Oruka Therapeutics Shareholders Back Governance and Executive Pay - TipRanks
Oruka Therapeutics (ORKA) investors approve directors, auditor and executive pay - Stock Titan
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
Oruka Therapeutics (ORKA) director awarded 9,136 stock options with 2036 expiry - Stock Titan
Oruka Therapeutics (ORKA) grants director 9,136 stock options - Stock Titan
Director at Oruka Therapeutics (ORKA) receives 9,136 stock options award - Stock Titan
Oruka Therapeutics (ORKA) director granted 9,136 stock options - Stock Titan
Oruka Therapeutics (NASDAQ: ORKA) grants 9,136-share option to Fairmount-managed funds - Stock Titan
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy - Investing.com
Oruka Therapeutics stock rating reaffirmed by Piper Sandler at Overweight - Investing.com Canada
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits - TipRanks
Oruka Therapeutics (NASDAQ: ORKA) widens IL-23 rights but delays IBD dosing - Stock Titan
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million - Yahoo Finance
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million - The Motley Fool
Number of shareholders of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
Number of shareholders of Oruka Therapeutics, Inc. – SWB:HQ1 - TradingView
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors - AOL.com
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Encouraging ORKA-001 Psoriasis Data and Upsized Offering Could Be A Game Changer For Oruka Therapeutics (ORKA) - Sahm
Oruka Therapeutics(ORKA.US) Director Sells US$6.19 Million in Common Stock - Moomoo
Wedbush Adjusts Price Target on Oruka Therapeutics to $165 From $85, Maintains Outperform Rating - Moomoo
Oruka Therapeutics director Carl Dambkowski sells $6.19m in stock - Investing.com India
Oruka Therapeutics Inc Stock (ORKA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Agarwal Arjun | Senior Vice President, Finance |
Jun 12 '26 |
Sale |
69.72 |
9,459 |
659,508 |
17,294 |
| Agarwal Arjun | Senior Vice President, Finance |
Jun 15 '26 |
Sale |
69.69 |
395 |
27,528 |
16,899 |
| Goncalves Joana | Chief Medical Officer |
Jun 15 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
40,665 |
| Goncalves Joana | Chief Medical Officer |
Jun 15 '26 |
Sale |
69.28 |
7,947 |
550,607 |
32,718 |
| Klein Lawrence Otto | Chief Executive Officer |
Jun 15 '26 |
Sale |
69.69 |
1,729 |
120,494 |
925,580 |
| Sandler Laura Lee | Chief Operating Officer |
Jun 15 '26 |
Sale |
69.69 |
600 |
41,814 |
236,384 |
| Quinlan Paul T | General Counsel |
Jun 15 '26 |
Sale |
69.69 |
733 |
51,083 |
31,034 |
| Dambkowski Carl | Director |
Jun 11 '26 |
Sale |
70.13 |
22,417 |
1,572,201 |
51,326 |
| Dambkowski Carl | Director |
Jun 12 '26 |
Sale |
70.11 |
12,583 |
882,182 |
38,743 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):